Mylatabi (Eltrombopag)

Eltrombopag acts as an agonist at the thrombopoietin receptor (c-Mpl) on megakaryocyte precursors. By stimulating this receptor, it triggers signaling pathways that promote the growth and maturation of megakaryocytes, the cells responsible for producing platelets, thereby increasing platelet numbers in the bloodstream.

The dosage of Mylatabi is individualized. A qualified prescriber determines the appropriate dose based on the patient’s specific condition, response to therapy, and laboratory values. Patients should follow the prescribing clinician’s instructions and not adjust the dose on their own.

The safety of eltrombopag in pregnancy and lactation has not been established. Because potential risks are unknown, it should only be used if the expected benefit justifies the possible danger to the fetus or infant. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mylatabi. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mylatabi (eltrombopag) and other agents such as romiplostim share the same therapeutic goal of increasing platelet production. Eltrombopag is an oral small‑molecule agonist, whereas romiplostim is administered by subcutaneous injection. Choice of therapy often depends on patient preference, route of administration, and specific clinical considerations.

Mylatabi should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Mylatabi is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed, unless the prescribing information advises otherwise. Dosing times and any food restrictions are determined by the treating physician.

Serious risks include hepatic failure, severe thrombotic events such as deep‑vein thrombosis or arterial clots, and rare cases of severe neutropenia or anaphylaxis. Patients should be monitored regularly for liver function abnormalities and signs of thrombosis, and any concerning symptoms should prompt immediate medical evaluation.

Mylatabi is contraindicated in patients with known hypersensitivity to eltrombopag or any of its excipients, and in individuals with active, uncontrolled thrombosis. Caution is also advised for patients with severe liver impairment, uncontrolled hypertension, or those receiving other thrombopoietin receptor agonists.